The American Diabetes Association (ADA) 2021 Standards of Medical Care in Diabetes now reflect new data on teplizumab and sodium-glucose cotransporter-2 inhibitors, as well as the effects of dapagliflozin and finerenone on patients with chronic kidney disease.
A systematic review and meta-analysis found that proton-pump inhibitors (PPIs) improved glycemic indices in patients with diabetes and did not appear to affect risk for incident diabetes.
Tirzepatide, a not-yet-approved dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, was tested against placebo and semaglutide in recent studies.
Sotagliflozin linked to more days alive, out of hospital in patients with type 2 diabetes recently hospitalized for heart failure
During a median of nine months of follow-up, daily treatment with 200 to 400 mg/d of the experimental drug was associated with about three more days alive and out of the hospital compared to placebo in an industry-funded randomized trial.
A study of National Health and Nutrition Examination Survey data from 2011 to 2018 found that 46.7% of respondents ages 60 years and older used aspirin for primary or secondary cardiovascular disease prevention and suggested potential overuse in certain groups.
Recalled syringes may have graduated markings that are printed incorrectly on the syringe barrel.
The recall includes two lots of metformin hydrochloride extended-release tablets USP (750 mg) manufactured in India and distributed in the U.S.